

**Lantheus Holdings, Inc.**  
**Reconciliation of GAAP to Non-GAAP Financial Measures**  
(in thousands, except per share data – unaudited)

	Three Months Ended					
	March 31, 2022			March 31, 2021		
	GAAP	Adjustments	Non-GAAP Adjusted	GAAP	Adjustments	Non-GAAP Adjusted
Revenues	\$ 208,880		\$ 208,880	\$ 92,509		\$ 92,509
Cost of goods sold <sup>(a)</sup>	79,810	(10,827)	68,983	51,479	(5,462)	46,017
Gross profit	129,070	10,827	139,897	41,030	5,462	46,492
Operating expenses						
Sales and marketing <sup>(b)</sup>	20,354	(1,013)	19,341	14,173	(642)	13,531
General and administrative <sup>(c)</sup>	37,588	(21,228)	16,360	16,138	(2,135)	14,003
Research and development <sup>(d)</sup>	12,203	(696)	11,507	10,360	(425)	9,935
Total operating expenses	70,145	(22,937)	47,208	40,671	(3,202)	37,469
Gain on sale of assets	—	—	—	15,263	(15,263)	—
Operating income	58,925	33,764	92,689	15,622	(6,599)	9,023
Interest expense	1,509	—	1,509	2,718	—	2,718
Gain on extinguishment of debt	—	—	—	(889)	889	—
Other income <sup>(e)</sup>	(485)	—	(485)	(549)	307	(242)
Income before income taxes	57,901	33,764	91,665	14,342	(7,795)	6,547
Income tax expense <sup>(f)</sup>	14,939	8,896	23,835	5,334	(2,083)	3,251
Net income	<u>\$ 42,962</u>	<u>\$ 24,868</u>	<u>\$ 67,830</u>	<u>\$ 9,008</u>	<u>\$ (5,712)</u>	<u>\$ 3,296</u>
Net income per common share - diluted	<u>\$ 0.61</u>		<u>\$ 0.97</u>	<u>\$ 0.13</u>		<u>\$ 0.05</u>
Weighted-average common shares outstanding - diluted <sup>(g)</sup>	<u>70,051</u>	<u>—</u>	<u>70,051</u>	<u>67,714</u>		<u>67,714</u>
Depreciation expense	\$ 3,091	—	\$ 3,091	\$ 3,046	—	\$ 3,046
Amortization expense	\$ 8,306	—	\$ 8,306	\$ 4,685	—	\$ 4,685

- (a) Includes stock and incentive plan compensation, amortization of acquired intangible assets, ARO acceleration and other related costs, integration costs and other non-recurring charges.
- (b) Includes stock and incentive plan compensation, integration costs and other non-recurring charges.
- (c) Includes stock and incentive plan compensation, acquisition-related costs, contingent consideration fair value adjustments, non-recurring strategic initiatives, integration costs and other non-recurring charges.
- (d) Includes stock and incentive plan compensation.
- (e) Includes amortization of fair value adjustments.
- (f) The income tax effect of the adjustments between GAAP net income (loss) and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
- (g) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP net loss position.

**Lantheus Holdings, Inc.**

**Reconciliation of GAAP to Non-GAAP Financial Measures**

(in thousands, except per share data – unaudited)

	Three Months Ended		
	March 31, 2022		
	GAAP	Adjustments	Non-GAAP Adjusted
Revenues	\$ 208,880		\$ 208,880
Cost of goods sold <sup>(a)</sup>	79,810	(10,827)	68,983
Gross profit	129,070	10,827	139,897
Operating expenses			
Sales and marketing <sup>(b)</sup>	20,354	(1,013)	19,341
General and administrative <sup>(c)</sup>	37,588	(21,228)	16,360
Research and development <sup>(b)</sup>	12,203	(696)	11,507
Total operating expenses	70,145	(22,937)	47,208
Operating income	58,925	33,764	92,689
Interest expense	1,509	—	1,509
Other income	(485)	—	(485)
Income before income taxes	57,901	33,764	91,665
Income tax expense <sup>(d)</sup>	14,939	8,896	23,835
Net income	\$ 42,962	\$ 24,868	\$ 67,830
Net income per common share - diluted	\$ 0.61		\$ 0.97
Weighted-average common shares outstanding - diluted <sup>(e)</sup>	70,051	—	70,051
Depreciation expense	\$ 3,091	—	\$ 3,091
Amortization expense	\$ 8,306	—	\$ 8,306

- (a) Includes stock and incentive plan compensation, amortization of acquired intangible assets, ARO acceleration and other related costs and other non-recurring charges.
- (b) Includes stock and incentive plan compensation.
- (c) Includes stock and incentive plan compensation, acquisition-related costs, contingent consideration fair value adjustments, non-recurring strategic initiatives and other non-recurring charges.
- (d) The income tax effect of the adjustments between GAAP net income (loss) and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
- (e) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP net loss position.

**Lantheus Holdings, Inc.**  
**Reconciliation of Non-GAAP Financial Measures**  
(in thousands – unaudited)

As shown below, the Company provides the components of Management EBITDA. Management EBITDA consists of; adjusted net income plus the remainder of depreciation, interest expense, net and income tax expense, net of indemnification income.

The below table presents Management EBITDA for the three months ended March 31, 2022 and 2021, respectively:

	Three Months Ended March 31,	
	2022	2021
Adjusted net income	\$ 67,830	\$ 3,296
Depreciation expense	3,091	3,046
Interest expense, net	1,501	2,701
Income tax expense <sup>(a)</sup>	23,439	2,678
Management EBITDA	\$ 95,861	\$ 11,721

(a) Represents income tax expense, less tax indemnification income.

**Lantheus Holdings, Inc.**  
**Reconciliation of P&L With & Without Novartis Agreement**  
(in thousands, except per share data – unaudited)

	Three Months Ended		
	March 31, 2022		
	Non-GAAP Adjusted	Adjustments	Non-GAAP Adjusted
Revenues <sup>(a)</sup>	\$ 208,880	\$ (24,000)	\$ 184,880
Cost of goods sold	68,983		68,983
Gross profit	139,897	(24,000)	115,897
Operating expenses			
Sales and marketing	19,341	—	19,341
General and administrative	16,360	—	16,360
Research and development	11,507	—	11,507
Total operating expenses	47,208	—	47,208
Operating income	92,689	(24,000)	68,689
Interest expense	1,509	—	1,509
Other income	(485)	—	(485)
Income before income taxes	91,665	(24,000)	67,665
Income tax expense <sup>(b)</sup>	23,835	(6,240)	17,595
Net income	<u>\$ 67,830</u>	<u>\$ (17,760)</u>	<u>\$ 50,070</u>
Net income per common share - diluted	<u>\$ 0.97</u>		<u>\$ 0.71</u>
Weighted-average common shares outstanding - diluted	<u>70,051</u>	<u>—</u>	<u>70,051</u>

(a) Includes Novartis Agreement.

(b) The income tax effect of the adjustments.